07.09.2011Augurix and Tillotts sign agreement for the commercialization of Simtomax.

You are here

Augurix and Tillotts sign agreement for the commercialization of Simtomax.

Augurix and Tillotts sign agreement for the commercialization of Simtomax® for rapid diagnosis of celiac disease.

View PDF

Find on a map Advanced search

BioAlps World Visibitlity Package 201918.03.2019

A yearly international programme for our affiliated companies to increase their visibility.

BioAlps World Visibitlity Package 2019

A yearly international programme for our affiliated companies to increase their visibility.

Tolerys SATherapeutics & Diagnostics, Other
Therapeutics & Diagnostics, Vaccines

Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.

Print this page

Download this page (PDF)

Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn

Powered by /boomerang